May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build ...

May 20, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build ...

Cingulate, Inc. (NASDAQ:CING) reported first quarter 2025 results ... For the quarter ending March 31 st, 2025, the company reported a net loss of ($3.8) million or ($1.04) per share.

Cingulate (NASDAQ:CING) stock is soaring over 160% in early trading and trending on many financial news websites. The rally was sparked by the company’s announcement that the Nasdaq exchange ...

Begin your TipRanks Premium journey today. Cingulate Inc (CING) Company Description: Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release ...

The latest price target for Cingulate (NASDAQ:CING) was reported by Roth Capital ... so you should get 4 ratings per company per firm each year. The last rating for Cingulate was filed on May ...

Cingulate (NASDAQ:CING – Get Free Report ... stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a ...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical ...